Stockscreener 앱 받기
4.90
1.41%
-0.07
시간 외 거래:
4.89
-0.01
-0.20%
전일 마감가:
$4.97
열려 있는:
$5
하루 거래량:
177.30K
Relative Volume:
3.81
시가총액:
$84.18M
수익:
$37.16M
순이익/손실:
$-17.83M
주가수익비율:
-4.7389
EPS:
-1.034
순현금흐름:
$-14.22M
1주 성능:
-4.30%
1개월 성능:
-12.34%
6개월 성능:
-11.07%
1년 성능:
-17.79%
1일 변동 폭
$4.7651
$5.15
1주일 범위
$4.7651
$5.85
52주 변동 폭
$3.28
$9.8212
Verrica Pharmaceuticals Inc Stock (VRCA) Company Profile
명칭
Verrica Pharmaceuticals Inc
전화
484-453-3300
주소
44 WEST GAY STREET, WEST CHESTER, PA
Compare VRCA vs VRTX, REGN, ARGX, RVMD, ONC
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
VRCA
Verrica Pharmaceuticals Inc
|
4.90 | 85.38M | 37.16M | -17.83M | -14.22M | -1.034 |
VRTX
Vertex Pharmaceuticals Inc
|
515.57 | 128.19B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
805.86 | 82.72B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
986.80 | 53.26B | 4.16B | 1.29B | 734.26M | 19.58 |
RVMD
Revolution Medicines Inc
|
211.94 | 43.66B | 742.00K | -1.37B | -1.07B | -7.0731 |
ONC
Beone Medicines Ltd Adr
|
362.66 | 39.31B | 5.76B | 514.49M | 1.10B | 4.4813 |
Verrica Pharmaceuticals Inc Stock (VRCA) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2024-11-06 | 다운그레이드 | H.C. Wainwright | Buy → Neutral |
| 2024-11-05 | 다운그레이드 | RBC Capital Mkts | Outperform → Sector Perform |
| 2023-07-25 | 업그레이드 | Needham | Hold → Buy |
| 2023-03-22 | 개시 | Jefferies | Buy |
| 2023-02-13 | 업그레이드 | RBC Capital Mkts | Sector Perform → Outperform |
| 2022-05-25 | 다운그레이드 | RBC Capital Mkts | Outperform → Sector Perform |
| 2021-05-14 | 개시 | RBC Capital Mkts | Outperform |
| 2020-12-24 | 재확인 | H.C. Wainwright | Buy |
| 2020-07-15 | 다운그레이드 | BofA Securities | Buy → Neutral |
| 2020-06-30 | 재확인 | H.C. Wainwright | Buy |
| 2020-06-24 | 개시 | Northland Capital | Outperform |
| 2020-03-24 | 개시 | Needham | Buy |
| 2019-02-21 | 개시 | H.C. Wainwright | Buy |
모두보기
Verrica Pharmaceuticals Inc 주식(VRCA)의 최신 뉴스
Verrica (VRCA) Q2 2026 Earnings Call Transcript - AOL.com
Verrica Pharmaceuticals (NASDAQ:VRCA) Rating Lowered to Strong Sell at Wall Street Zen - marketbeat.com
Verrica Revenue Falls Despite Record YCANTH Demand - MyChesCo
Verrica Pharmaceuticals Inc. R (1NE0.DU) balance sheet - Yahoo Finance UK
Q2 2026 Verrica Pharmaceuticals Inc Earnings Call Transcript - GuruFocus
Verrica Pharmaceuticals Inc. R (1NE0.DU) stock price, news, quote and history - Yahoo Finance UK
Verrica Pharmaceuticals Q2 Earnings Call Highlights - MarketBeat
Verrica secures $27.5 million credit facility from chairman By Investing.com - Investing.com South Africa
Verrica Pharmaceuticals (NASDAQ:VRCA) Releases Earnings Results - MarketBeat
Earnings call transcript: Verrica Q2 2026 loss widens as YCANTH sales rise - Investing.com
Verrica Pharmaceuticals earnings missed by $0.08, revenue topped estimates - Investing.com Canada
Verrica Q2 2026 Earnings: YCANTH Growth Was Masked by a Milestone Comparison - TradingKey
Is Verrica Pharmaceuticals (VRCA) a Hidden Gem After Q2 Earnings - GuruFocus
Verrica Pharmaceuticals Inc. (VRCA) Reports Q2 Loss, Beats Revenue Estimates - Yahoo Finance
Verrica Pharmaceuticals Inc reports results for the quarter ended June 30Earnings Summary - TradingView
Verrica Pharmaceuticals Inc. 2026: Revenue $5.86M, EPS ($0.62) — 10-Q Summary - TradingView
Verrica secures $27.5 million credit facility from chairman - Investing.com
Verrica Reports Q2 Revenue of $5.9 Million as YCANTH Demand Rises - Quiver Quantitative
Verrica Pharmaceuticals reports Q2 2026 revenue $5.9M, net loss $13.2M; YCANTH demand up - TradingView
Verrica Pharmaceuticals Inc. (VRCA) Q2 FY2026 earnings call transcript - Yahoo Finance
Verrica Pharma reports wider-than-expected Q2 adj loss per share - TradingView
Verrica Pharmaceuticals Reports Second Quarter 2026 Financial Results - manilatimes.net
YCANTH applicator units reach 19,626; common-wart data expected mid-2027 - Stock Titan
Press Release: Verrica Pharmaceuticals Closes Credit Facility For Up To $27.5 Million in Non-Dilutive Growth Capital - Moomoo
Verrica Pharmaceuticals Closes Credit Facility For Up To $27.5 Million in Non-Dilutive Growth Capital - GlobeNewswire
Verrica Schedules Aug. 6 Earnings Call With Corporate Update - MyChesCo
Verrica Pharmaceuticals Inc expected to post a loss of 38 cents a shareEarnings Preview - TradingView
Verrica Pharmaceuticals Inc. R (1NE0.DU) Options Chain - Yahoo! Finance Canada
Graphique interactif des capital-actions 1NE0.SG| Capital-actions Verrica Pharmaceuticals Inc. - Yahoo Finance France
Verrica Pharmaceuticals (VRCA) Projected to Release Quarterly Earnings on Thursday - marketbeat.com
Verrica Pharmaceuticals to Report Second Quarter 2026 - GlobeNewswire
Verrica Sets Aug. 6 Webcast to Discuss Second-Quarter Results - Stock Titan
Verrica Pharmaceuticals (VRCA) Slips Over 4% as Shares Test Near-Term Support at $4.92Dark Pool Prints - dars.gov.et
Verrica Expands YCANTH Rights to Israel in Licensing Deal - MyChesCo
VRCA|Verrica Pharmaceuticals Inc|Price:4.935|Chg%:+0.075 - TradingKey
Verrica Pharmaceuticals Inc (VRCA) Shareholder Structure: Major Shareholders & Institutional Holdings - TradingKey
VRCA|Verrica Pharmaceuticals Inc|Price:5.020|Chg%:-0.420 - TradingKey
Verrica Pharmaceuticals Inc (VRCA) Institutional Confidence - TradingKey
TradingKey - TradingKey
Verrica Pharmaceuticals Inc. (NASDAQ:VRCA) Given Consensus Recommendation of "Hold" by Brokerages - marketbeat.com
Verrica Pharmaceuticals Inc (VRCA) Dividends & Stock Splits: Historical Payouts and Event Timeline - TradingKey
Verrica Pharmaceuticals Inc. Revenue Breakdown – NASDAQ:VRCA - TradingView
Verrica Pharmaceuticals Inc (VRCA) Risk Assessment: Volatility, Financial Risk & Investment Risk - TradingKey
Verrica grants Medomie exclusive rights for YCANTH in Israel By Investing.com - Investing.com Nigeria
Verrica grants Medomie exclusive rights for YCANTH in Israel - Investing.com
Verrica Pharmaceuticals and Medomie Pharma Enter into Exclusive Distribution, Marketing and Supply Agreement to Commercialize YCANTH® for the Treatment of Molluscum Contagiosum in Israel - The Manila Times
Verrica deal could bring YCANTH to Israeli children if approved - Stock Titan
VERRICA PHARMACEUTICALS INVESTIGATION CONTINUED BY FORMER LOUISI - GuruFocus
Verrica Pharmaceuticals (VRCA) Slides 4.13% as Resistance Holds FirmFibonacci Arc - dars.gov.et
Verrica Pharmaceuticals holds the spotlight after recent market context - ad-hoc-news.de
Q1 2026 Verrica Pharmaceuticals Inc Earnings Call Transcript - GuruFocus
Verrica Pharmaceuticals Inc (VRCA) 재무 분석
매출
순이익
현금흐름
주당 순 이익
Verrica Pharmaceuticals Inc 주식 (VRCA) 내부자 거래
| 내부자 거래 | 관계 | 날짜 | 거래 | 비용 | #주식 | 가치 ($) | #주식 총계 |
|---|---|---|---|---|---|---|---|
| Kirby John J. | Interim CFO |
Nov 25 '25 |
Buy |
4.24 |
3,536 |
15,001 |
8,962 |
| Zawitz David | Chief Operating Officer |
Nov 25 '25 |
Buy |
4.24 |
10,000 |
42,425 |
21,000 |
| Rieger Jayson | CEO and President |
Nov 25 '25 |
Buy |
4.24 |
94,311 |
400,114 |
182,593 |
| Manning Paul B | Director |
Nov 25 '25 |
Buy |
4.24 |
2,750,762 |
11,670,108 |
3,348,372 |
| Manning Paul B | Director |
Nov 25 '25 |
Buy |
4.24 |
1,375,380 |
5,835,050 |
3,958,189 |
2.20%
0.07%
자본화:
|
볼륨(24시간):